1. Pink Sheet

Same-Day BLA Filings Show Pfizer Has Gained Ground On Novartis In Meningitis B

Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.

Novartis AG appears to has lost some ground to Pfizer Inc. in the competition to launch the first vaccine for meningitis B in the U.S. – both firms announced BLA filings June 17, but Pfizer has completed its rolling submission and Novartis is still in progress.

Novartis’ Bexsero obtained European approval in 2012 and is on the market now in 34 countries, but Pfizer is catching up with its vaccine candidate LP2086

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D